Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial)
Cardiovascular Drugs and Therapy · 2025
DOI: 10.1007/s10557-024-07576-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Shin Ito und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research and Development, National Cerebral and Cardiovascular Center, Suita, Japan. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Heart Failure. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Kowa Company.
Themen: Diabetes mellitus, Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Recent large clinical trials have revealed that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes not only in patients with heart failure with reduced ejection fraction, but also in patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF). However, the effect of SGLT2 inhibitors on left ventricular (LV) diastolic function is still controversial. METHODS AND RESULTS: The TOP-HFPEF trial (Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus) is a multicenter, double-arm, open-label, confirmatory, investigator-initiated clinical study to investigate the effect of SGLT2 inhibitor on LV diastolic function in patients with HFpEF and type 2 diabetes mellitus. The participants are randomly assigned (1:1) to the tofogliflozin group (20 mg once daily) or the control group (administration or continuation of antidiabetic drugs other than SGLT2 inhibitors). The estimated number of patients to be enrolled in this trial is 90 in total (45 in each group). The participants are followed up for 52 weeks with tofogliflozin or control drugs. The primary endpoint is the change in E/e' assessed by echocardiography from the baseline to the end of this study (52 weeks). This trial will also evaluate the effects of tofogliflozin on cardiovascular events, biomarkers, other echocardiographic parameters, the occurrence of atrial fibrillation, and renal function. CONCLUSIONS: The TOP-HFPEF trial will clarify the efficacy of an SGLT2 inhibitor, tofogliflozin, on LV diastolic function in patients with HFpEF and type 2 diabetes mellitus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Research and Development, National Cerebral and Cardiovascular Center, Suita, Japan.
- Department of Heart Failure and Transplant, National Cerebral and Cardiovascular Center, Suita, Japan.
- Cardiovascular Center, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, Osaka, Japan.
- Department of Cardiology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.
- Department of Cardiology, Baba Memorial Hospital, Sakai, Japan.
- Department of Cardiovascular Medicine, Sakai City Medical Center, Sakai, Japan.
ORCID-Profile: Masafumi Kitakaze
Förderung
- Kowa Company
Zitieren
APA
Ito, S., Nakajima, Y., Fukuda, H., Izumi, C., Nakazawa, G., Yamashita, H., Matsuhisa, H., Inoko, M., Toyoda, S., Takiuchi, S., Kataoka, T., Izumiya, Y., Abe, Y., Sozu, T., Sakata, Y., Emoto, M., Inoue, T., & Kitakaze, M. (2025). Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial). Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07576-y
Vancouver
Ito S, Nakajima Y, Fukuda H, Izumi C, Nakazawa G, Yamashita H, et al. Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial). Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-024-07576-y
BibTeX
@article{Ito2025,
author = {Ito, Shin and Nakajima, Yuri and Fukuda, Hiroki and Izumi, Chisato and Nakazawa, Gaku and Yamashita, Hajime and Matsuhisa, Hideo and Inoko, Moriaki and Toyoda, Shigeru and Takiuchi, Shin and Kataoka, Toru and Izumiya, Yasuhiro and Abe, Yukio and Sozu, Takashi and Sakata, Yasushi and Emoto, Masanori and Inoue, Teruo and Kitakaze, Masafumi},
title = {Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial)},
journal = {Cardiovascular Drugs and Therapy},
year = {2025},
doi = {10.1007/s10557-024-07576-y}
}
EUVIMED